Trials / Unknown
UnknownNCT05795296
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
Clinical Study of Fruquintinib in Combination With Sintilimab as a First-line Therapy in Gastric Adenocarcinoma/Adenocarcinoma of Esophagogastric Junction
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to explore the efficacy and safety in patients with gastric adenocarcinoma or adenocarcinoma of esophagogastric junction. The main questions it aims to answer are: * Does this therapy have a promising efficacy? * Does this therapy have a manageable toxicity? Participants will receive fruquintinib plus sintilimab as first-line therapy for gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib | Fruquintinib: 5mg po, d1-d14, q3w |
| DRUG | Sintilimab | Sintilimab: 200mg ivgtt, d1, q3w |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2024-08-31
- Completion
- 2025-08-31
- First posted
- 2023-04-03
- Last updated
- 2023-08-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05795296. Inclusion in this directory is not an endorsement.